Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab | Zendy

Anil Kumar Gupta | Zendy; Yaneicy GonzalezRojas | Zendy; Erick Stanley Petersen Juárez | Zendy; Manuel Crespo Casal | Zendy; Jaynier Moya | Zendy; Diego R. Falci | Zendy; Elias Sarkis | Zendy; Joel Solis | Zendy; Hanzhe Zheng | Zendy; Nicola Scott | Zendy; Andrea L. Cathcart | Zendy; Christy M. Hebner | Zendy; Jennifer E. Sager | Zendy; Erik Mogalian | Zendy; Craig Tipple | Zendy; Amanda Peppercorn | Zendy; Elizabeth Alexander | Zendy; Phillip S. Pang | Zendy; Almena Free | Zendy; Cynthia Brinson | Zendy; Melissa Aldinger | Zendy; Adrienne E. Shapiro | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Author(s) -

Anil Kumar Gupta,

Yaneicy GonzalezRojas,

Erick Stanley Petersen Juárez,

Manuel Crespo Casal,

Jaynier Moya,

Diego R. Falci,

Elias Sarkis,

Joel Solis,

Hanzhe Zheng,

Nicola Scott,

Andrea L. Cathcart,

Christy M. Hebner,

Jennifer E. Sager,

Erik Mogalian,

Craig Tipple,

Amanda Peppercorn,

Elizabeth Alexander,

Phillip S. Pang,

Almena Free,

Cynthia Brinson,

Melissa Aldinger,

Adrienne E. Shapiro

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2107934

Subject(s) - medicine , placebo , interim analysis , adverse effect , population , relative risk , confidence interval , randomization , randomized controlled trial , pathology , alternative medicine , environmental health

Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization or death in older patients and those with underlying conditions. Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent progression of Covid-19 in high-risk patients early in the course of disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research